
5W0G-50819

A Phase III study evaluating carboplatin/paclitaxel or carboplatin/paclitaxel/bevacizumab (bev) with or without concurrent cetuximab (cet) in advanced NSCLC

- Estimated primary completion: June 2012 (Target N = 1,546)
- Eligibility: Newly diagnosed Stage IV disease OR recurrent disease after prior surgery and/or irradiation; no prior chemotherapy for any stage NSCLC; no prior EGFR- or VEGF-targeted agents





DR HERBST

I am the national principal investigator on the SWOG-S0819 trial. It's designed to evaluate

a population of patients who have an increase in the EGFR gene copy number by FISH. It is an important trial to determine a more specific role for cetuximab in lung cancer. All patients have tissue samples taken at the time of enrollment. Patients are randomly assigned to carboplatin/paclitaxel or carboplatin/paclitaxel/bevacizumab, with or without cetuximab. The question of the percent of patients with an increased EGFR gene copy number will be investigated prospectively. We're making sure that we have the results so that we can look back to see if, in fact, that marker is predictive of outcome. To make the trial more user friendly and to allow physicians to administer treatment to patients as they would off study, bevacizumab is allowed for those who have not experienced any problems with bleeding and have nonsquamous NSCLC or brain metastases, if treated.



DR SOCINSKI

We've seen a number of trials with cetuximab — some positive, some negative. Most of the data

are relatively underwhelming. Honestly, I believe this trial will "seal the fate" of cetuximab in lung cancer.

The 10th Annual

Winter Lung Cancer

Conference

